BRAF and skin cancer: Additionally, considering BRAF is activated by RAS-dependent dimerization69, this mechanism leads to paradoxical trans-activation of the pathway during V600E/K-specific BRAF inhibitor treatment, which has been identified to cause secondary skin cancers and general skin toxicities79.